Every new ADHD drug announcement gets filed under “sounds nice, check back in three years.” I get it. The gap between a press release and a pill in your hand is usually measured in years, not months.

But yesterday’s news from Alkermes is a different kind of interesting, and not because of the numbers alone (though the numbers are good). It’s interesting because of what the drug is. ALKS 7290 is an orexin 2 receptor agonist — a drug class that, until September 21, 2026, had never shown a clinically meaningful benefit for ADHD in a controlled trial. Orexin agonists exist because of narcolepsy, a condition where the brain doesn’t make enough of this particular wakefulness signal. Nobody was building this class for attention and focus. And now one has cleared proof-of-concept for exactly that.

That’s the headline. Here’s what’s actually in the data, and what it does (and doesn’t) mean for you right now.

TL;DR

What	The short version
The drug	ALKS 7290, an orexin 2 receptor (OX2R) agonist from Alkermes
The milestone	First orexin agonist to show clinically meaningful ADHD symptom reduction in a controlled trial
Phase 1b trial	50 adults with ADHD, double-blind, placebo-controlled, 14 days
Results	Median AISRS reductions of 14.0 points (20mg) and 19.0 points (50mg)
Safety	Generally well tolerated; no serious adverse events; no discontinuations
What’s next	Phase 2 already dosing (~312 adults), data expected in 2027

One-sentence verdict: This is real, early, non-stimulant proof-of-concept for a mechanism nobody expected to work on ADHD — but “Phase 2 data in 2027” means this changes nothing about your medication plan today.

Best for: Anyone tracking the non-stimulant pipeline because current options haven’t been enough Skip if: You need something to act on this week. This is a three-year-minimum story, at best.

What Is an Orexin Receptor Agonist?

Orexin (also called hypocretin) is a brain chemical that regulates wakefulness, arousal, and motivation. An orexin receptor agonist is a drug that activates orexin receptors to boost that signal. The drug class was developed almost entirely for narcolepsy, a disorder caused by orexin deficiency. ALKS 7290 targets the OX2R subtype specifically, and until this trial, nothing in the class had been tested against ADHD symptoms with a positive result.

Why Would a Narcolepsy Drug Target Do Anything for ADHD?

It sounds like a stretch until you look at what orexin neurons actually do. They project into the same arousal and reward circuits that ADHD research has been circling for years — the systems that regulate whether your brain treats a task as worth staying engaged with. Orexin deficiency in narcolepsy doesn’t just cause sleepiness. It flattens motivation and attentional stability too, which is part of why narcolepsy and ADHD symptoms overlap more than most people realize.

That overlap is presumably the theory Alkermes was betting on. Betting on a theory and having it survive contact with a controlled trial in actual ADHD patients are two very different things, though, and that’s the gap this Phase 1b closes. Alkermes also reported that EEG biomarkers and cognitive testing — attention, working memory, processing speed — moved in the same direction as the symptom scale, with changes showing up as early as day 6. That kind of convergence, a subjective symptom scale and objective cognitive testing pointing the same way, is what makes a proof-of-concept result harder to wave off as noise.

What Actually Happened in the Trial

Alkermes ran a double-blind, placebo-controlled Phase 1b study in 50 adults with ADHD. Participants went through a two-week medication washout, then spent 14 days on either 20mg or 50mg of ALKS 7290 daily (split dosing), or placebo, randomized roughly 4-to-1 in favor of the active drug.

The primary measure was the Adult ADHD Investigator Symptom Rating Scale (AISRS), a 54-point clinician-rated scale. Participants started with a median score around 39, which puts the group solidly in moderate-to-severe territory.

Here’s where it gets interesting:

Dose	Median AISRS reduction from baseline	CGI-S shift
20mg	14.0 points	1.0-point reduction
50mg	19.0 points	2.0-point reduction

The Clinical Global Impression-Severity (CGI-S) numbers translate roughly to “markedly or moderately ill” shifting toward “mildly ill” on the 50mg dose. And the effect wasn’t slow to build — improvements showed up by day 6 and held through day 14, according to STAT News’ coverage of the announcement.

I want to be precise about what “clinical proof-of-concept” means here, because trial-speak gets stretched in press releases constantly. It doesn’t mean “this works.” It means the drug moved the needle on the exact scale you’d want it to move, at a dose and duration small enough that nobody’s betting the company on it yet. That’s the bar this data cleared. Nothing more, nothing less.

The Safety Picture, Briefly

No serious adverse events. No discontinuations among people taking ALKS 7290. Most side effects were mild: insomnia, more frequent urination, dizziness, some change in sustained attention, and constipation.

For anyone who’s spent years navigating the stimulant shortage and its scheduling headaches: ALKS 7290 doesn’t touch dopamine the way stimulants do. It’s working an entirely different receptor system, and nothing in the released data or the coverage around it raised abuse-potential concerns. That’s not a formal abuse-liability finding (those studies come later), but it’s a meaningfully different starting point than a dopaminergic compound.

Phase 2 Is Already Underway

This part actually surprised me. Alkermes didn’t wait around. A Phase 2 trial is already dosing patients: roughly 312 adults with ADHD, tested across multiple dosing regimens against placebo, with the first participant dosed in September 2026. The primary endpoint is AISRS change from baseline at week 4. Data is expected in 2027.

That’s a fast follow. It also means “2027” is the earliest point where you’ll have anything resembling a real answer on whether this holds up in a bigger, longer trial. Phase 3 hasn’t started. FDA review hasn’t started. If you’re doing napkin math on when this could actually be prescribable, you’re looking at 2029 at the absolute earliest, and that’s if everything goes right, which it usually doesn’t.

Where This Fits in the Non-Stimulant Pipeline

ALKS 7290 isn’t the only new mechanism that’s moved through trials this year. Centanafadine — FDA-approved as Simtriyo back on July 24 — is a triple reuptake inhibitor, targeting norepinephrine, dopamine, and serotonin together. That’s a genuinely different approach from ALKS 7290, which doesn’t touch any of those three systems directly. Between the two, you’ve got two completely distinct new mechanisms reaching human ADHD data in the same year, after roughly two decades of the field mostly rearranging the same handful of neurotransmitters.

I don’t think that’s a coincidence so much as it is a sign that the ADHD drug pipeline has actual money and actual novel science behind it right now, instead of just line extensions.

These two candidates also have something in common besides timing: trial data for both showed no euphoria signal, the kind of finding that points toward a less restrictive DEA schedule than stimulants get. Simtriyo is already testing that theory — it’s FDA-approved but still waiting on the DEA to actually assign it a schedule before it can reach a pharmacy counter. If ALKS 7290 eventually clears that same bar, the practical upside isn’t just “another pill.” It’s the possibility of fewer DEA quota fights, fewer months of rationed pharmacy supply, and, potentially, an easier prior-authorization conversation with insurance than a Schedule II stimulant currently requires. None of that is guaranteed — Simtriyo’s own approved label still carries a boxed warning for abuse and misuse, and it could still land on Schedule II. Scheduling and coverage decisions happen well after approval, and approval for ALKS 7290 is still years out. But it’s the direction both of these are pointing.

What This Means for Your Stack Today

Nothing changes for you this week. I’ll say that plainly because press releases about promising early trials are exactly the kind of thing that can send you down a research rabbit hole (you know the one — sixteen tabs deep into pharmacology forums by 11pm) when the actual actionable takeaway is “file this away and check back in a year.”

A few honest notes if you want to do something with this information:

1. Don’t ask your prescriber about it yet. There’s no dosing data beyond Phase 1b, no safety data beyond 14 days, and no drug to prescribe. Bring it up in eighteen months, not eighteen days.
2. If you’re on the fence about medication generally, this is one more data point that the field is actively expanding options beyond “stimulant or nothing.” The BMJ’s massive treatment review still shows medication and CBT as the strongest evidence-based interventions available right now, and that doesn’t change based on a Phase 1b readout.
3. Keep building the systems that don’t depend on any specific drug. Whatever ALKS 7290 turns into, your task-initiation strategies and evidence-based productivity approaches are the layer that works regardless of what’s in your medicine cabinet.

The Realistic Timeline

Phase 1b done. Phase 2 dosing now, data in 2027. Phase 3 not started. FDA review not started. That’s the honest sequence, and it’s worth sitting with, because “first-in-class breakthrough” headlines have a way of collapsing that timeline in people’s heads down to “coming soon.”

What makes this worth tracking anyway is the mechanism, not the calendar. Twenty years of ADHD treatment options built almost entirely on dopamine and norepinephrine, and now a drug built for narcolepsy patients is showing it can move ADHD symptom scores in a controlled trial. Whether it survives Phase 2 and beyond is a real, open question. That an orexin drug got this far at all is the part that wasn’t supposed to happen.

---

Your one action item: If you’re actively unhappy with your current medication (or lack of one), don’t wait on ALKS 7290. Talk to your prescriber about what’s actually available now, including where Simtriyo (centanafadine) stands — FDA-approved, still waiting on DEA scheduling before it’s actually prescribable. Set a calendar reminder for mid-2027 to check on Phase 2 results, and let this one go until then.